Publications by authors named "Keaven Anderson"

Claim this Profile
S
Software for complex group sequential designs.
Yujie Zhao, Keaven Anderson

Contemp Clin Trials· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prior Effective Sample Size When Borrowing on the Treatment Effect Scale.
Hongtao Zhang, Keaven M Anderson, Zachary Zimmer, Gregory Golm, Aditi Sapre

Stat Med· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjusted Inference for Multiple Testing Procedure in Group-Sequential Designs.
Yujie Zhao, Qi Liu, Linda Z Sun, Keaven M Anderson

Biom J· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploratory subgroup identification in the heterogeneous Cox model: A relatively simple procedure.
Larry F León, Thomas Jemielita, Zifang Guo, Rachel Marceau West, Keaven M Anderson

Stat Med· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The MaxCombo Test Severely Violates the Type I Error Rate-Reply.
Pralay Mukhopadhyay, Satrajit Roychoudhury, Keaven M Anderson

JAMA Oncol· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Electronic common technical document submission with analysis using R.
Yujie Zhao, Nan Xiao, Keaven Anderson, Yilong Zhang

Clin Trials· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A gated group sequential design for seamless Phase II/III trial with subpopulation selection.
Guanhong Miao, Jason J Z Liao, Jing Yang, Keaven Anderson

BMC Med Res Methodol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A unified framework for weighted parametric group sequential design.
Keaven M Anderson, Zifang Guo, Jing Zhao, Linda Z Sun

Biom J· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Log-Rank Test vs MaxCombo and Difference in Restricted Mean Survival Time Tests for Comparing Survival Under Nonproportional Hazards in Immuno-oncology Trials: A Systematic Review and Meta-analysis.
Pralay Mukhopadhyay, Jiabu Ye, Keaven M Anderson, Satrajit Roychoudhury, Eric H Rubin

JAMA Oncol· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multiplicity for a group sequential trial with biomarker subpopulations.
Ting-Yu Chen, Jing Zhao, Linda Sun, Keaven M Anderson

Contemp Clin Trials· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
On the empirical choice of the time window for restricted mean survival time.
Lu Tian, Hua Jin, Hajime Uno, Ying Lu, Bo Huang, Keaven M Anderson

Biometrics· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Using artificial intelligence tools in answering important clinical questions: The KEYNOTE-183 multiple myeloma experience.
Jason J Z Liao, Mohammed Z H Farooqui, Patricia Marinello, Jonathan Hartzel, Keaven Anderson

Contemp Clin Trials· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rejoinder to Letter to the Editor "The Hazards of Period Specific and Weighted Hazard Ratios".
Ray S Lin, Ji Lin, Satrajit Roychoudhury, Keaven M Anderson, Tianle Hu

Stat Biopharm Res· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pembrolizumab Exposure-Response Assessments Challenged by Association of Cancer Cachexia and Catabolic Clearance.
David C Turner, Anna G Kondic, Keaven M Anderson, Andrew G Robinson, Edward B Garon

Clin Cancer Res· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab.
Richard W Joseph, Jeroen Elassaiss-Schaap, Richard Kefford, Wen-Jen Hwu, Jedd D Wolchok, Keaven M Anderson

Clin Cancer Res· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab.
Richard W Joseph, Jeroen Elassaiss-Schaap, Richard Kefford, Wen-Jen Hwu, Jedd D Wolchok, Keaven M Anderson

Clin Cancer Res· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A 2-in-1 adaptive phase 2/3 design for expedited oncology drug development.
Cong Chen, Keaven Anderson, Devan V Mehrotra, Eric H Rubin, Archie Tse

Contemp Clin Trials· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Stepwise two-stage sample size adaptation.
Hong Wan, Susan S Ellenberg, Keaven M Anderson

Stat Med· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Information-based sample size re-estimation in group sequential design for longitudinal trials.
Jing Zhou, Adeniyi Adewale, Yue Shentu, Jiajun Liu, Keaven Anderson

Stat Med· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
University of Pennsylvania 6th annual conference on statistical issues in clinical trials: Dynamic treatment regimes (morning session).
Keaven Anderson, Marshall Joffe, Michael R Kosorok

Clin Trials· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
On efficient two-stage adaptive designs for clinical trials with sample size adjustment.
Qing Liu, Gang Li, Keaven M Anderson, Pilar Lim

J Biopharm Stat· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The BATTLE trial: a bold step toward improving the efficiency of biomarker-based drug development.
Eric H Rubin, Keaven M Anderson, Christine K Gause

Cancer Discov· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Viewpoints on the FDA draft adaptive designs guidance from the PhRMA working group.
Paul Gallo, Keaven Anderson, Christy Chuang-Stein, Vladimir Dragalin, Brenda Gaydos

J Biopharm Stat· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fitting spending functions.
Keaven M Anderson, Jason B Clark

Stat Med· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Finding the right dose for cancer therapeutics--can we do better?
Eric H Rubin, Keaven M Anderson

Clin Cancer Res· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis